Travere Therapeutics, Inc., (Nasdaq: TVTX) today announced that William Rote, Ph.D., the Company’s chief research officer, plans to retire from the Company in February 2027 following 10 years of ...

AZN's Ultomiris wins FDA priority review for IgAN, backed by late-stage data showing a 43.4% proteinuria reduction versus ...

Is TVTX a good stock to buy? We came across a bullish thesis on Travere Therapeutics, Inc. on Biotech Distilled’s Substack.

Wells Fargo analyst Mohit Bansal maintained a Buy rating on Travere Therapeutics yesterday and set a price target of $65.00. Designed for personal research, portfolio monitoring, and AI-assisted ...

Detailed price information for Rocket Pharmaceuticals Inc (RCKT-Q) from The Globe and Mail including charting and trades.

Healthcare companies balance science, innovation and hope in the pursuit of better diagnostics, treatments and even cures, ...

As part of the campaign, AKF has enhanced its webpage on FSGS with expanded information on diagnosis, treatment options and types of FSGS. AKF also created accompanying digital guides for patients on ...

In its largest acquisition to date, Incyte Inc. snagged rights to phase III-stage VGA-039, a monoclonal antibody the firm said could offer a new standard of care in von Willebrand disease (VWD), in a ...

A series of major studies has shown that finerenone preserves kidney function, reduces cardiovascular risk, and improves survival across a much broader range of patients with chronic kidney disease ...

Everest Medicines (HKEX 1952.HK) announced that it has entered into an exclusive licensing and collaboration agreement with Travere Therapeutics, Inc.